From Research at med.fsu.edu Fri Mar 5 15:33:24 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 5 Mar 2021 20:33:24 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <3F30A99C-45EA-4BA1-8930-A7289070B206@fsu.edu> References: <3F30A99C-45EA-4BA1-8930-A7289070B206@fsu.edu> Message-ID: Fahs-Beck Fund for Research and Experimentation: Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows) Grants of up to $25,000 are available to help support the research of faculty members or post-doctoral researchers of accredited universities or colleges in the United States and Canada. Areas of interest for funding are: studies to develop, refine, evaluate, or disseminate interventions and preventive/intervention to address social, psychological, behavioral or public health problems affecting children, adults, couples, families, and communities with outcomes that have the potential add to the knowledge base for services and program development. Community engaged research is highly valued. Due April 1, 2021. Med-RA deadline to receive draft documents: March 22. UF CTSI Learning Health System Initiative: Translational Pilot (RFA attached) The UF CTSI Learning Health System Program is pleased to invite applications for Translational Pilot Awards that use a ?learning health system? approach to align research and clinical operations to improve health outcomes and advance health equity using informatics, stakeholder engagement, implementation science and other methodologies to address one or more priority areas at UF Health including potentially preventable admissions and readmissions, decision support and/or particular conditions including: hypertension, diabetes, and opioid and other substance use. Two 12-month awards of up to $50,000 each are available for pilot projects that address health-related research questions developed in collaboration with clinicians, patients and community groups or other stakeholders. Research teams should demonstrate an established partnership with clinicians, patients, and other stakeholders as appropriate for the research. Once complete, these pilot projects should provide a solid foundation on which to base applications for extramural funding. Due April 2, 2021. Med-RA deadline to receive draft documents: March 22. James S. McDonnell Foundation Opportunity Awards: Understanding Human Cognition The James S. McDonnell Foundation (JSMF) supports research on understanding human cognition across the fields of cognitive science, cognitive psychology and developmental science. The Opportunity Awards were initiated because the foundation believes the time is right to advance the understanding of human cognition and behavior via a developmental science approach. With the Opportunity Awards, JSMF is seeking to fund projects leading to new conceptual and empirical studies of cognition and behavior that recognize the dynamic nature of cognition and behavior, are situated in real world contexts, cross levels of analysis, unite traditionally separate domains of inquiry (e.g. vision and speech), embrace complexity, and consider how behavior is influenced by interactions among individuals. $250,000 / 2-4 year projects. Due April 9, 2021. Med-RA deadline to receive draft documents: March 29. Prostate Cancer Foundation?Pfizer Health Equity Challenge Awards The intent of this Request for Proposal is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management, and outcomes of prostate cancer patients in minority and underserved communities. General research proposals in the following topic areas are of particular interest: * Identification of barriers in the delivery of equitable healthcare * Health services research programs to study and optimize care delivery $100,000?$150,000 / 1 year projects Letter of intent due April 9, 2021. Med-RA deadline to receive draft documents: March 29. Provider?s Clinical Support System ? Universities The Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, is accepting applications for fiscal year 2021 Provider?s Clinical Support System ? Universities grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder seeking or receiving MAT through ensuring the education and training of students in the medical, physician assistant, and nurse practitioner fields. This program?s focus is to ensure students fulfill the training requirements needed to obtain a DATA waiver to prescribe MAT in office-based settings. The desired outcomes include: 1. an increase in the number of individuals completing the training requirements for the DATA waiver; 2. an increase the number of individuals with a DATA waiver; and 3. an ultimate increase in those prescribing. Eligible applicants are medical schools, physician assistant schools, and schools of nursing (programs for nurse practitioners). 3-year projects / $150,000 per year. Due April 20, 2021. Med-RA deadline to receive draft documents: April 7. ADDF-Harrington Scholar Program The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer?s disease and related dementias. This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer?s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. Average award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period. Funding Priorities Drug Targets The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly: * Epigenetics (including nucleosome dynamics, chromatin remodeling, DNA methylation, histone modifications [methylation, acetylation, phosphorylation, ubiquitylation, sumoylation], bromodomain protein modulators, isocitrate dehydrogenase modulators) * Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance) Other Novel Targets are Encouraged These include, but are not limited to: * Neurovascular health * Neuroprotection * Synaptic activity and neurotransmitters * Inflammation * Mitochondria & metabolic function * ApoE * Other aging targets (e.g. senescent cells) Any therapeutic target that has a clear marker of target engagement or one in development will be considered of high priority. Letter of intent due April 23, 2021. Application due July 30, 2021. Med-RA deadline to receive draft documents for letter of intent: April 12. PCORI Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19 Building Capacity for PCOR/CER for Topics Related to COVID-19 is a research support ? not research?special funding opportunity for projects up to 18 months in duration and up to $200,000 in total costs. This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to COVID-19. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest. In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects: * Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results. * Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER. * Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER in a new population or geographic area. This is an opportunity to explore and address the urgent and unique needs to build capacity for stakeholder engagement in PCOR/CER specifically related to: * Long-term effects of post-acute COVID-19; * Impact of COVID-19 on disproportionately affected populations; * Impact of COVID-19 on social isolation and loneliness (mental health and well-being); and * Engaging, educating, and promoting informed decision making around COVID-19 vaccines. Other relevant topics related to COVID-19 health outcomes with appropriate justification will also be considered. $200,000 / 18-month projects. Due May 24, 2021. Med-RA deadline to receive draft documents: May 11. PCORI Engagement Award Special Cycle: Building Capacity for PCOR/CER in Intellectual and Developmental Disabilities This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to intellectual and developmental disabilities (IDD). Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest. In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects: * Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results. * Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER. * Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER in a new population or geographic area. This is an opportunity to build capacity for stakeholder engagement with PCOR/CER in IDD on topics such as: * Addressing health equity and advancing IDD health outcomes for vulnerable populations * Leveraging community-based and patient-centered models of care delivery * Challenges related to clinical care delivery and access * Telehealth solutions * Transition to adulthood * Caregiver needs and access to wraparound support * Patient needs and preferences Other relevant topics related to IDD health outcomes with appropriate justification are welcomed. $250,000 / 2-year projects. Due May 24, 2021. Med-RA deadline to receive draft documents: May 11. Robert Wood Johnson Foundation's Systems for Action: Systems and Services Research to Build a Culture of Health Achieving racial equity and health equity in American communities requires effective solutions to the ?wrong-pocket problem?: we invest in systems that are designed to improve social and economic conditions?such as housing, transportation, education, income, and employment assistance; child and family supports; and legal and criminal justice services?but the financial benefits of these often flow elsewhere, in reduced costs for medical care from diseases and injuries prevented. This creates imbalances in power, information, and financial resources that exist across medical, social, and public health systems?a fundamental problem that confronts many attempts at meaningful cross-sector collaboration. Such solutions must allow collaborating organizations to equitably share in the costs and the benefits of multisector collaborative initiatives, and to share in the power and influence that govern these initiatives. This call for proposals will provide funding for new research to rigorously test and evaluate innovative solutions to the wrong-pocket problem that persists across health and social service systems. This call for proposals will support studies that can be completed over a 36-month period with up to $500,000 in total funding from RWJF. Up to four awards will be selected for funding under this solicitation. Due June 9, 2021. Med-RA deadline to receive draft documents: May 26. Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21 / R33 ? Clinical Trial Optional) The Agency for Healthcare Research and Quality?s mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Standard dates apply. Expires July 18, 2021. Med-RA deadline to receive draft documents for June 16 due date: June 3. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: LHS RFP FINAL 2021_03_04.pdf Type: application/pdf Size: 97241 bytes Desc: LHS RFP FINAL 2021_03_04.pdf URL: From Research at med.fsu.edu Fri Mar 12 14:26:46 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 12 Mar 2021 19:26:46 +0000 Subject: Weekly funding opportunities In-Reply-To: <505B1225-136B-49C0-BBA8-E3331A3827B2@fsu.edu> References: <505B1225-136B-49C0-BBA8-E3331A3827B2@fsu.edu> Message-ID: Congressionally Directed Medical Research Programs Lung Cancer Research Program Career Development Award Pre-application (required letter of intent): April 6. Full application: April 20. Concept Award Pre-application (required letter of intent): April 6. Full application: April 20. Med-RA deadline to receive draft documents for April 20 full application due date: April 7. Clinical Translational Research Partnership Award Pre-application (required letter of intent): July 14. Full application: July 28. Med-RA deadline to receive draft documents for July 14 full application due date: June 30 (due to July 4 holiday). Investigator Initiated Translational Research Award Pre-application (preproposal): May 5. Invited full application: July 28. Med-RA deadline to receive draft documents for May 5 preproposal due date: April 22. WITH Foundation: Comprehensive Healthcare for Adults with Developmental Disabilities Established in 2002, the WITH Foundation works to provide comprehensive health care for adults with developmental disabilities that addresses their unique and fundamental needs. To that end, the foundation welcomes Letters of Intent from organizations in support of efforts to promote comprehensive health care for adults with developmental disabilities. Grants will be awarded in support of programs that improve delivery of health care to adult consumers with developmental disabilities and that include at least one of the following facets: improve health practitioner competency through education and/or training programs; address the currently inadequate reimbursement system; advance formal care coordination; enhance public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; increase understanding of supported decision making in healthcare settings; conduct national efforts in digital health that support designers and developers and that include the perspectives/experiences of the IDD community within the design process in order to create better technology for all; conduct social policy research; and identify and overcome barriers to high-quality healthcare access. The foundation typically provides a year of support of between $30,000 and $50,000 but may cover as much as three years to support programming that warrants extended funding. Letter of intent due April 9, 2021. Med-RA deadline to receive draft documents: March 29. NIOSH Support for Conferences and Scientific Meetings (U13 Clinical Trial Not Allowed) The purpose of the NIOSH Support for Conferences and Scientific Meetings (U13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSH?s scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health. The conference program is integral to the overall mission of NIOSH. An application should address and advance important areas of research in the field of occupational safety and health of particular interest to NIOSH programs and the National Occupational Research Agenda. A conference or scientific meeting is defined as a gathering, symposium, seminar, workshop or any other organized and formal meeting where persons assemble in person or meet virtually to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge. Standard dates apply. Expires December 15, 2025. Med-RA deadline to receive draft documents for April 12 standard date: March 30. The Midlife in the United States Study ? Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit Alzheimer?s disease and Alzheimer?s disease related dementias (AD/ADRD)-focused U01s that are ancillary to, but integrated with, the Midlife in the United States Study (MIDUS) U19 (see PAR-21-156) to provide in-depth information to elucidate behavioral, social, psychological and biological pathways of risk and resilience to cognitive decline and AD/ADRD. In addition to capitalizing on already-collected data, new measures should be included to test hypotheses regarding development of AD/ADRD via cumulative stress exposures over 30 prior years of data collection. As well, the research should examine the protective influence of psychosocial resources, affective style, and lifestyle factors assessed over multiple prior waves of MIDUS. The new assessments on two national samples with many years of information on potential influences on AD/ADRD hold potential for yielding invaluable insights relevant for preventative interventions and treatments in future studies. Due April 26, 2021 and November 18, 2021. Med-RA deadline to receive draft documents for April 26 due date: April 13. Alex?s Lemonade Stand: Crazy 8 Initiative (Pediatric Cancers) The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of new cure discovery. Investigations may involve the exploration of a novel scientific hypothesis or the development of new model systems, tools or technologies that have the potential for significant impact on the field of childhood cancer. Collaboration and resource sharing are a priority for this research program. We expect successful applications to propose multidisciplinary teams with a very clear plan for collaboration that would empower the study of big ideas that would not be easily addressable otherwise. Childhood cancer research applicants are encouraged to bring new, necessary expertise into the field. For 2021, priority will be given to projects involving innovative studies of high-grade gliomas, nonmedulloblastoma embryonal brain tumors, non-Ewing Sarcoma fusion-positive sarcomas, fusion-negative sarcomas, big data and/or catalyzing clinical trials. Depending on the type of project and the size of the team, the requested budget should be in the range of $3-5 million USD over four years. Letter of intent due April 26, 2021. Med-RA deadline to receive draft documents: April 13. Simons Foundation Autism Research Initiative: Human Cognitive and Behavioral Science Grants awarded through this RFA are intended to produce foundational knowledge about the neurobehavioral differences associated with ASD, which will directly inform the development or refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis is placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better triangulate phenotypic and neurobiological variability within and across individuals with ASD. The maximum budget is $750,000 or less, inclusive of 20 percent indirect costs, over a period of up to three years. Due May 3, 2021. Med-RA deadline to receive draft documents: April 20. Focused Ultrasound Foundation Clinical and Pre-clinical Awards Program Tracks include Brain and Cancer Immunotherapy. Clinical Awards The Foundation funds first-in-human and other innovative clinical trials involving the use of image-guided focused ultrasound to treat diseases. Funding for clinical trials is determined through a peer-review process, and the timing and dollar amounts are determined on a case-by-case basis. Priority is given to clinical indications with a clear patient need. Pre-clinical Awards Our Pre-Clinical Awards Program support investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. This program typically does not fund large capital purchases, overhead or institutional expenses, and the development of new focused ultrasound equipment. Exceptions to these guiding principles may be considered if the project addresses a gating factor in the near-term development of a reimbursable clinical application. Robust scientific design is prioritized over positive results (high failure risk is acceptable), and translational projects are preferred. General Awards Program: Clinical Track and High-Risk Track As a Pre-clinical Program Track, the General Awards Program provides funding for investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. The Pre-Clinical Track is geared primarily toward pre-clinical research and projects targeting one clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years. The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated. One-page research abstracts accepted any time. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. Due June 2, 2021. Med-RA deadline to receive draft documents: May 19 (due to Memorial Day holiday). New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery. Due June 5, 2021; October 5, 2021; February 5, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024. Med-RA deadline to receive draft documents for June 5 due date: May 24. NIMH Mental Disorders FOAs: R01s, R34, R33s, U01, R61 / R33s The NIMH is soliciting clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA is designed for applicants seeking funding for multi-site collaborative clinical trials to establish the effectiveness of interventions. Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions. Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) The purpose of this FOA is to encourage pilot research consistent with NIMH?s priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a prerequisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support ?go/no-go? decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention?s efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention?s potential for significant clinical benefit. First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug?s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to ?de-risk? novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH?s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support ?go/no-go? decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH?s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention?s impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the ?go/no-go? milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support ?go/no-go? decisions about further development and/or testing of the intervention. Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Due June 15, 2021; October 15, 2021; February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2022; June 15, 2023; October 17, 2023; February 15, 2024. Med-RA deadline to receive draft documents for June 15 due date: June 2. Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed) This funding opportunity announcement solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. The Tropical Medicine Research Centers (TMRCs) are intended to advance NIAID?s global research effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries (LMICs), as classified by the World Bank; create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, and/or vector control strategies. Due June 18, 2021. Med-RA deadline to receive draft documents: June 7. Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed) This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D. Due June 22, 2021. Med-RA deadline to receive draft documents: June 9. Triadic Interactions in Clinical Encounters Involving People with Alzheimer?s Disease and Alzheimer?s Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications focused on triadic interactions and interpersonal processes between individuals with Alzheimer?s disease or Alzheimer?s disease-related dementias (AD/ADRD), clinicians, and care partners. NIA seeks to increase our understanding of the impact of such interactions on patient health and well-being outcomes. The goal of this initiative is to identify targets for the development of behavioral interventions to optimize interactions in clinical settings and help build and preserve strong and supportive caregiving relationships throughout all stages of AD/ADRD and across the continuum of care. To these ends, this FOA solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters. Due June 23, 2021. Med-RA deadline to receive draft documents: June 10. Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) To support the design of novel tuberculosis vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones. Due June 30, 2021. Med-RA deadline to receive draft documents: June 17. EMDR Foundation Research Grants Grant awards of up to $25,000 are available for post-doctoral students, university faculty, or clinicians conducting research on Eye Movement Desensitization and Reprocessing (EMDR). Current research priorities include: 1st Priority ? Advancing Evidence Based Practice: Increase the availability of quality EMDR research in areas where we already have a foot-hold in the literature but where more evidence is needed. Specifically, those areas are in the use of EMDR therapy to treat: * Anxiety * Depression * Military PTSD * Phantom Limb Pain * To enhance recovery from the impact of cardiac events and the diagnosis and treatment of cancer 2nd Priority ? Addressing the Global Burden of Trauma: Investigate the use of EMDR in natural or man-made disaster responses, by determining the effectiveness of the following protocols: early intervention protocols, the child or adult group protocols, or the use of EMDR standard protocols in disaster response. 3rd Priority ? Building Clinical Evidence: There are a number of areas where EMDR therapy is being used, clinical observations are positive, and there are some research indicators of success. However, more research is needed to build a body of literature in these populations or diagnostic categories, including but not limited to: * Addictions * Eating disorders * Dissociative disorders * Additional medical/somatic conditions * Suicide prevention and/or to address the impact of suicide These priorities apply to research across the lifespan. Due July 1, 2021. Med-RA deadline to receive draft documents: June 21. Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement is to solicit applications to expand basic research on non-polio enteroviruses (NPEV) that will inform the development of pan-enterovirus vaccines and broad-spectrum antivirals against enteroviruses A, B, C, and D. Due July 13, 2021. Med-RA deadline to receive draft documents: June 29 (due to July 4 holiday). Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research. Due October 25, 2021 and October 25, 2022. Med-RA deadline to receive draft documents for October 2021 due date: October 12. Forecasts Research Grants for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional) Estimated post date: May 1, 2021 Estimated application due date: October 1, 2021 The National Cancer Institute intends to solicit applications that will support transdisciplinary research projects on the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk. Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional) Estimated post date: April 9, 2021 Estimated application due date: August 20, 2021 The National Institute on Minority Health and Health Disparities, with other NIH Institutes, Centers, and Offices, intends to promote a new initiative soliciting applications on (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities. Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional) Estimated post date: May 1, 2021 Estimated application due date: September 1, 2021 This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will also examine the complex mechanisms and effectors that direct the proliferation and expansion of tumor initiating cells and their progeny to initiate these cancers. The focus of the FOA will be on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestation or neoplasia. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Mar 26 14:14:29 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 26 Mar 2021 18:14:29 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <18D1F3FF-74B9-4A46-B86E-886923F8F621@fsu.edu> References: <18D1F3FF-74B9-4A46-B86E-886923F8F621@fsu.edu> Message-ID: NSF Dear Colleague Letter: Tool Development for Cell Biology (Tools4Cells) As scientists? abilities to open new frontiers in cell biological research continue to be limited by current technologies, there is still a need for the development of new tools and methods to advance our understanding of cells, especially using interdisciplinary approaches that can leverage advances in other fields and apply them to cell biology. Technological advancements have had a profound and catalytic influence on the field of cell biology, either through the application of existing technologies to the study of cellular processes in new and creative ways, or through the development of novel technologies to study areas not previously possible. Relatively recent examples of such advances include: methods of molecular dynamics simulations to study membrane protein signal transmission; gene-editing technologies such as CRISPR/Cas9 applied to probe gene localization; development of new single molecule fluorescence/microscopy techniques to enable in vivo single cell dynamic measurements; single cell sequencing; and the application of cryo-EM and x-ray free electron lasers to the study of protein structure and dynamics. The purpose of this Dear Colleague Letter (DCL) is to encourage submission of proposals to develop novel tools and methods that improve scientists? abilities to manipulate, control, analyze, or measure critical aspects of cells and their functions in order to open new areas of study in cell biology. Proposals for new tools or methods developments in cell biology can include, but are not limited to the general areas of bioinformatics, instrumentation, or laboratory or field-based research methods. Proposals should be submitted to one of two Divisions in the Directorate for Biological Sciences (BIO) depending on the range of applicability of the tool or method and its connection to a specific research question rather than a general topical area. The research cluster and program within the two BIO divisions that seek proposals in this area are: * Cellular Dynamics and Function Cluster in BIO?s Division of Molecular and Cellular Biology (MCB) if the proposed tool or method addresses a specific research question or hypothesis defined by and to be used by an individual user or group of researchers. Such a project would be evaluated on the importance of the research question or hypothesis and the potential of the tool or method to improve scientists? ability to study cells or their function related to the question or hypothesis. In addition, for some efforts, the research community is encouraged to take risks in exploring new tools or methods with the potential to change understanding of how cells work. * Infrastructure Innovation for Biological Research Program in BIO?s Division of Biological Infrastructure (DBI) if the proposed tool or method is applicable to a broad class of biological research questions or topics and will meet the needs of a well-defined community of researchers. Such a project would be evaluated on its responsiveness to a well-defined research question in BIO, the specific BIO-funded research community that would benefit, a clear demonstration of how the innovation represents an advance over currently available tools or methods, and the quality of the project management description. Although this DCL is encouraging submissions related to cell biology, this program and all other DBI programs invite proposals on any area of biology that fit within its guidelines. Proposals responsive to this DCL should be submitted as follows based on the above criteria: * Cellular Dynamics and Function Cluster via the MCB core solicitation (currently NSF 21-509). However, for the projects that are ?high-risk/high-payoff?, investigators should consider the Early-Concept Grants for Exploratory Research (EAGER) type of proposal which allows requests for up to $300,000 over two years. Specific instructions for preparation and submission of EAGER proposals can be found in Chapter II.E.2 of the NSF Proposal & Award Policies & Procedures Guide (PAPPG). * Infrastructure Innovation for Biological Research Program via the DBI solicitation (currently NSF 21-502). Proposals may be submitted at any time. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Michael J. Fox Foundation: Promoting Diversity, Equity and Inclusion in Parkinson?s Disease Research The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson?s disease in populations that have been excluded from or underrepresented in research. Though no definitive evidence exists that the incidence, morbidity, or mortality of Parkinson?s disease (PD) varies between socioeconomic and ethnic groups, data on traditionally underrepresented groups is either sparse or nonexistent. This request for applications to promote diversity, equity and inclusion in Parkinson?s research is open to proposals that will increase inclusivity and broaden our understanding of PD. Such projects will help accelerate the discovery of strategies for reducing risk and developing treatments for all people. Applicants may request budgets starting from $50,000 up to $400,000, depending on the scope of work for 18 to 36 months. Applications should focus on studies in underrepresented populations around one or more of the following Parkinson?s areas: * Disease burden: Research toward robust estimates of PD incidence and/or prevalence * Risk and pathology: Diagnostic, biomarker, and/or pathological evaluations to better understand Parkinson?s risk and pathology, and discern how they intersect with the social determinants of health and structural discrimination * Assessments: Evaluation of assessment procedures across different cultures and differential response to treatment * Clinical course: Investigation of how Parkinson?s disease progresses in different populations and likelihood of milestones for advanced disease such as cognitive impairment, refractory motor symptoms and loss of independence * Access to care: Exploration of structural barriers that prevent access to neurology evaluations and care, and access to/uptake of device-aided therapies Pre-proposals due April 21, 2021. Med-RA deadline to receive draft documents: April 8. HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research ? for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease. Due April 27, 2021; June 22, 2021; October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023. Med-RA deadline to receive draft documents for April 27, 2021 due date: April 14. Congressionally Directed Medical Research Programs Autism Research Program Clinical Trial Award Pre-application: May 3, 2021. Invited full application: August 5, 2021. Idea Development Award Pre-application: May 3, 2021. Invited full application: August 5, 2021. Clinical Translational Research Award Pre-application: May 3, 2021. Invited full application: August 5, 2021. Career Development Award Pre-application: May 3, 2021. Invited full application: August 5, 2021. Med-RA deadline to receive draft documents for the above pre-applications: April 20. Peer Reviewed Cancer Research Program FY 2021 topic areas: bladder cancer; blood cancers; brain cancer; cancers associated with the use of beryllium; colorectal cancer; endometrial cancer, esophageal cancer; germ cell cancers; head and neck cancers; liver cancer; lymphoma, mesothelioma, and metastatic cancers; neuroblastoma, pediatric, adolescent, and young adult cancers; pediatric brain tumors, stomach cancer; sarcoma; thyroid cancer; and the link between scleroderma and cancer. Behavioral Health Science Award Pre-application (required letter of intent): July 29. Full application: August 18. Career Development Award - Fellow Option Pre-application (required letter of intent): July 29. Full application: August 18. Med-RA deadline to receive draft documents for the above full applications: July 19. Idea Award Pre-application: May 20. Invited full application: September 8. Impact Award Pre-application: May 20. Invited full application: September 8. Med-RA deadline to receive draft documents for the above pre-applications: May 10. Translational Team Science Award Pre-application (required letter of intent): July 29. Full application: August 18. Med-RA deadline to receive draft documents for full application: July 19. Peer Reviewed Medical Research Program FY 2021 topic areas: arthritis, burn pit exposure, congenital heart disease, diabetes, dystonia, eating disorders, emerging viral diseases, endometriosis, epidermolysis bullosa, familial hypercholesterolemia, fibrous dysplasia, focal segmental glomerulosclerosis, food allergies, Fragile X, frontotemporal degeneration, hemorrhage control, hepatitis B, hydrocephalus, hypertension, inflammatory bowel diseases, malaria, metals toxicology, mitochondrial disease, myalgic encephalomyelitis / chronic fatigue syndrome, myotonic dystrophy, non-opioid therapy for pain management, nutrition optimization, pathogen-inactivated blood products, peripheral neuropathy, plant-based vaccines, platelet-like cell production, polycystic kidney disease, pressure ulcers, pulmonary fibrosis, respiratory health, rheumatoid arthritis, sleep disorders and restriction, suicide prevention, sustained release drug delivery, vascular malformations, women?s heart disease. Clinical Trial Award Pre-application: May 13. Invited full application: August 26. Med-RA deadline to receive draft documents for pre-application: May 3. Discovery Award Pre-application (required letter of intent): April 29. Full application: May 13. Med-RA deadline to receive draft documents for full application: May 3. Focused Program Award Pre-application: May 13. Invited full application: August 26. Med-RA deadline to receive draft documents for pre-application: May 3. Investigator Initiated Research Award Pre-application: April 28. Invited full application: September 2. Med-RA deadline to receive draft documents for pre-application: April 15. Technology / Therapeutic Development Award Pre-application: April 28. Invited full application: September 2. Med-RA deadline to receive draft documents for pre-application: April 15. Tick-Bourne Disease Research Program Career Development Award Pre-application: May 26. Invited full application: August 27. Idea Development Award Pre-application: May 26. Invited full application: August 27. Med-RA deadline to receive draft documents for the above pre-applications: May 13. Gordon and Betty Moore Foundation: Development of Clinical Quality Measures to Improve Diagnosis In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the United States. In other words, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process. To help address the problem, grants of up to $500,000 over eighteen months will be awarded to support the development of innovative clinical quality measures that promote excellence in diagnosis of three categories of disease that comprise the most common and most harmful diagnostic errors, acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia), and cancer (such as lung and colorectal cancer). The expected work requires two interlinked activities: 1) development of the rationale for a measure; and 2) operationalizing the measure into an algorithm. Due May 10, 2021. Med-RA deadline to receive draft documents: April 27. Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trial Not Allowed) The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development: For example, advanced courses in a specific discipline or research area, clinical procedures for research, or specialized research techniques. This FOA is to support courses for skills development in cross-cutting methodologies and analytics that are needed to advance behavioral and social sciences research (BSSR) but are not well addressed by existing educational programs widely available to the BSSR community. Short courses supported by this FOA should develop, implement, evaluate and disseminate education and training focused on innovative methods for BSSR. Methodological domains of focus include but are not limited to innovative data collection methodologies and analytic techniques, analysis and linking of big data, or needed but underutilized designs to advance research across the translational spectrum. Due June 4, 2021 (non-AIDS) and September 7, 2021 (AIDS). Med-RA deadline to receive draft documents for June 4, 2021 due date: May 24. Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 / R01 Clinical Trial Optional) R21 R01 A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for June 5, 2021 R01 standard date: May 24; and June 16, 2021 R21 standard date: June 3. Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs? (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn. Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3. High-Priority Behavioral and Social Research Networks in Alzheimer?s Disease and Alzheimer?s Disease-Related Dementias (R24 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer?s disease and Alzheimer?s disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in large population panel studies to support AD/ADRD research as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; measurement for dementia care in home and community-based services; the dementia care workforce; and education and AD/ADRD. Due June 23, 2021. Med-RA deadline to receive draft documents: June 10. High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health and Retirement Study international aging studies; biomarker collection in population studies; and innovation in longitudinal aging studies. Due June 23, 2021. Med-RA deadline to receive draft documents: June 10. Data Science: Infectious and Immune-mediated Diseases (R21 / U01 Clinical Trial Not Allowed) Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. Due July 2, 2021; February 17, 2022; July 1, 2022; February 17, 2023; and July 6, 2023. Med-RA deadline to receive draft documents for July 2, 2021 due date: June 21. Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3 / UH3 Clinical Trial Optional) The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program. Due August 10, 2021; February 9, 2022; August 9, 2022; February 9, 2023; August 9, 2023; and February 9, 2024 plus standard AIDS dates through May 7, 2024. Med-RA deadline to receive draft documents for August 10, 2021 due date: July 28. Primals Research Awards: Intriguing for Social, Behavioral, and Psychology Researchers The University of Pennsylvania Positive Psychology Center, with support from the Templeton Religion Trust, is pleased to announce the Primals Research Awards. Our goal is to promote new empirical research exploring how primal world beliefs(?primals?) are formed, maintained, change, or influence nontrivial outcomes or psychological processes. As recently introduced(Clifton et al., 2019; https://tinyurl.com/y4m62r7k), primals are basic perceptions of the general character of the world as a whole, such as the world is dangerous and the world is interesting, that correlate with many behaviors and wellbeing-related variables. We are awarding one$250,000 award and two $125,000 awards that will be administered over 24 months(July1, 2022 to June30,2024) to Principal Investigators proposingto examine primals from any of the following eight disciplinary perspectives: Clinical Psychology, Positive Psychology, Health Psychology, Organizational Psychology, Political Psychology, Personality Psychology, Social Psychology, and Developmental Psychology. LOI due September 26, 2021. Med-RA deadline to receive draft documents: September 14. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: